Tout­ing its man­u­fac­tur­ing strengths, Tot Bio­pharm rais­es $102M mega-round to ramp up can­cer R&D

The mega-round club of Chi­na’s on­col­o­gy drug­mak­ers is just get­ting start­ed.

In the lat­est, Suzhou-based Tot Bio­pharm closed $102 mil­lion in Se­ries B cash to fu­el R&D of the 10 drugs in its pipeline. Ex­ist­ing in­vestors Vi­vo Cap­i­tal, Cen­ter Lab­o­ra­to­ries, Cheng­wei Cap­i­tal, Yuan­ta Fi­nan­cial Hold­ings Group and Cathay Cap­i­tal were joined by Chi­na Uni­ver­sal — a huge in­vest­ment man­age­ment firm with a broad fo­cus — along­side “sev­er­al renowned do­mes­tic and for­eign in­vestors.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER